Anoro Ellipta cleared in Japan

The Japanese Ministry of Health, Labor and Welfare approves GlaxoSmithKline (GSK) and Theravance's (THRX) Anoro Ellipta (umeclidinium/vilanterol) for the relief of various symptoms of chronic obstructive pulmonary diseases in patients who require the concurrent use of a long-acting inhaled muscarinic antagonist and a long-acting inhaled beta2 agonist.

Anoro is a once-daily treatment comprised of two broncodilators. Umeclidinium is the muscarinic antagonist and vilanterol is the beta2 agonist.

Under the terms of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of $10M based on Japanese regulatory approval.

From other sites
Comments (3)
  • Cheriac
    , contributor
    Comments (19) | Send Message
    I own THRX and TBPH. What is the difference in the two companies. Can someone help me. This sounds like TBPH should be affected not THRX.


    4 Jul 2014, 11:29 PM Reply Like
  • John Vincent
    , contributor
    Comments (430) | Send Message
    Hi Cheriac,


    TBPH was spun out of THRX last month. TBPH is an early stage biotech that will have an 85% economic interest in the programs partnered with Glaxo that are still in research phase (Phase II and below drugs in the pipeline).


    THRX is now a royalty business that will get royalties from Glaxo for a couple of drugs that have blockbuster potential: RELVAR®/BREO® ELLIPTA® ("Relvar/Breo") and ANORO™ ELLIPTA™. There is also a third drug called Vibativ (FDA-approved injectible antibiotic to treat patients with hospital-acquired and ventilator associated bacterial pneumonia) and they will also have a 15% economic interest in TBPH's programs.


    Management have said that TBPH is similar to THRX of a few years ago. The business structure of new THRX is some what similar to PDLI and that is something you could look at.


    All the best,
    5 Jul 2014, 01:11 AM Reply Like
  • Cheriac
    , contributor
    Comments (19) | Send Message
    Thanks for the excellent explanation!
    5 Jul 2014, 02:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs